Pfizer Inc. $PFE Holdings Raised by DMKC Advisory Services LLC

Key Points

• DMKC Advisory Services LLC increased its holdings in Pfizer Inc. by 18.3% in Q2, now owning 69,020 shares valued at $1,697,000.
• Pfizer reported a quarterly earnings per share of $0.78, surpassing estimates and demonstrating a 10.3% year-over-year revenue increase.
• Analysts have mixed views on Pfizer, with target prices ranging from $25.00 to $33.00, leading to an average rating of Hold.

DMKC Advisory Services LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 18.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 69,020 shares of the biopharmaceutical company's stock after buying an additional 10,679 shares during the period. DMKC Advisory Services LLC's holdings in Pfizer were worth $1,697,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Capital Advisory Group Advisory Services LLC increased its position in Pfizer by 2.9% during the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock worth $328,000 after acquiring an additional 388 shares during the period. Trust Co of the South increased its holdings in shares of Pfizer by 1.5% during the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock worth $712,000 after purchasing an additional 441 shares during the period. Charter Oak Capital Management LLC raised its position in shares of Pfizer by 4.3% in the second quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company's stock valued at $258,000 after buying an additional 444 shares in the last quarter. Ballentine Partners LLC boosted its stake in shares of Pfizer by 0.5% in the second quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company's stock valued at $2,260,000 after buying an additional 458 shares during the period. Finally, Members Trust Co grew its position in Pfizer by 2.1% during the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock worth $587,000 after buying an additional 467 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

NYSE:PFE opened at $27.21 on Thursday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The business has a fifty day simple moving average of $24.59 and a two-hundred day simple moving average of $24.14. The company has a market capitalization of $154.68 billion, a P/E ratio of 14.47, a P/E/G ratio of 0.82 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same period in the previous year, the business earned $0.60 earnings per share. The firm's quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on PFE shares. Bank of America upped their target price on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Wall Street Zen cut shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday. UBS Group reissued a "neutral" rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday. Morgan Stanley upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Finally, Citigroup boosted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $28.29.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.